On Friday, Caribou Biosciences Inc (NASDAQ: CRBU) opened lower -7.09% from the last session, before settling in for the closing price of $1.41. Price fluctuations for CRBU have ranged from $1.22 to $8.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 71.11% annually for the last half of the decade. Company’s average yearly earnings per share was noted -20.17% at the time writing. With a float of $79.15 million, this company’s outstanding shares have now reached $90.55 million.
In an organization with 158 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.15%, operating margin of -1439.5%, and the pretax margin is -1289.12%.
Caribou Biosciences Inc (CRBU) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Caribou Biosciences Inc is 12.59%, while institutional ownership is 60.03%. The most recent insider transaction that took place on Feb 21 ’25, was worth 4,811. In this transaction Chief Legal Officer of this company sold 3,564 shares at a rate of $1.35, taking the stock ownership to the 443,502 shares. Before that another transaction happened on Feb 21 ’25, when Company’s Chief Business Officer sold 3,564 for $1.35, making the entire transaction worth $4,811. This insider now owns 66,936 shares in total.
Caribou Biosciences Inc (CRBU) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -20.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.22% during the next five years compared to -37.16% drop over the previous five years of trading.
Caribou Biosciences Inc (NASDAQ: CRBU) Trading Performance Indicators
Check out the current performance indicators for Caribou Biosciences Inc (CRBU). In the past quarter, the stock posted a quick ratio of 7.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -1.86 in one year’s time.
Technical Analysis of Caribou Biosciences Inc (CRBU)
Let’s dig in a bit further. During the last 5-days, its volume was 1.03 million. That was inferior than the volume of 1.39 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 64.81%. Additionally, its Average True Range was 0.10.
During the past 100 days, Caribou Biosciences Inc’s (CRBU) raw stochastic average was set at 5.06%, which indicates a significant decrease from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.00% in the past 14 days, which was lower than the 73.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5944, while its 200-day Moving Average is $2.0431. However, in the short run, Caribou Biosciences Inc’s stock first resistance to watch stands at $1.3933. Second resistance stands at $1.4767. The third major resistance level sits at $1.5233. If the price goes on to break the first support level at $1.2633, it is likely to go to the next support level at $1.2167. Assuming the price breaks the second support level, the third support level stands at $1.1333.
Caribou Biosciences Inc (NASDAQ: CRBU) Key Stats
There are currently 90,553K shares outstanding in the company with a market cap of 118.62 million. Presently, the company’s annual sales total 34,480 K according to its annual income of -102,070 K. Last quarter, the company’s sales amounted to 2,020 K and its income totaled -34,680 K.
